Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirmatrelvir/Ritonavir (Paxlovid) in Standard-Risk COVID-19 Patients
NCT05011513Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Aug 2021
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing PF-07321332/ritonavir with Placebo (2 arms). Primary endpoint: Time to Sustained Alleviation of Overall COVID-19 Signs and Symptoms at Day 28. Started Aug 2021; status: terminated.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05011513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011513.